Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Pharmacokinetics, disposition, and metabolism of bicifadine in the mouse, rat, and monkey.

Musick TJ, Gohdes M, Duffy A, Erickson DA, Krieter PA.

Drug Metab Dispos. 2008 Feb;36(2):241-51. Epub 2007 Nov 8.

PMID:
17991767
2.

In vitro metabolism of the analgesic bicifadine in the mouse, rat, monkey, and human.

Erickson DA, Hollfelder S, Tenge J, Gohdes M, Burkhardt JJ, Krieter PA.

Drug Metab Dispos. 2007 Dec;35(12):2232-41. Epub 2007 Sep 19.

PMID:
17881661
3.

Myocardial gene transfer and long-term expression following intracoronary delivery of adeno-associated virus.

Kaspar BK, Roth DM, Lai NC, Drumm JD, Erickson DA, McKirnan MD, Hammond HK.

J Gene Med. 2005 Mar;7(3):316-24.

PMID:
15515115
4.

Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450.

Erickson DA, Mather G, Trager WF, Levy RH, Keirns JJ.

Drug Metab Dispos. 1999 Dec;27(12):1488-95.

PMID:
10570031
5.

Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 8. 8-Aryloxymethyl- and 8-arylthiomethyldipyridodiazepinones.

Cywin CL, Klunder JM, Hoermann M, Brickwood JR, David E, Grob PM, Schwartz R, Pauletti D, Barringer KJ, Shih CK, Sorge CL, Erickson DA, Joseph DP, Hattox SE.

J Med Chem. 1998 Jul 30;41(16):2972-84.

PMID:
9685236
6.

Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 7. 8-Arylethyldipyridodiazepinones as potent broad-spectrum inhibitors of wild-type and mutant enzymes.

Klunder JM, Hoermann M, Cywin CL, David E, Brickwood JR, Schwartz R, Barringer KJ, Pauletti D, Shih CK, Erickson DA, Sorge CL, Joseph DP, Hattox SE, Adams J, Grob PM.

J Med Chem. 1998 Jul 30;41(16):2960-71.

PMID:
9685235
7.

The distribution, elimination, and in vivo biotransformation of aldicarb in the rainbow trout (Oncorhynchus mykiss).

Schlenk D, Erickson DA, Lech JJ, Buhler DR.

Fundam Appl Toxicol. 1992 Jan;18(1):131-6.

PMID:
1601201
8.

The acute myocardial infarction patient receiving tissue-type plasminogen activator.

Erickson DA, Kleven M.

J Emerg Nurs. 1988 Jul-Aug;14(4):253-9. No abstract available.

PMID:
3137390
9.
10.

The effects of noise upon human hearing sensitivity from 8000 to 20 000 Hz.

Fausti SA, Erickson DA, Frey RH, Rappaport BZ, Schechter MA.

J Acoust Soc Am. 1981 May;69(5):1343-7.

PMID:
7240565
11.

The effects of impulsive noise upon human hearing sensitivity (8 to 20 kHz).

Fausti SA, Erickson DA, Frey RH, Rappaport BZ.

Scand Audiol. 1981;10(1):21-9.

PMID:
7209369
12.

Effects of steady-state noise upon human hearing sensitivity from 8000 to 20 000 Hz.

Erickson DA, Fausti SA, Frey RH, Rappaport BZ.

Am Ind Hyg Assoc J. 1980 Jun;41(6):427-32.

PMID:
7395756
13.

A system for evaluating auditory function from 8000--20 000 Hz.

Fausti SA, Frey RH, Erickson DA, Rappaport BZ, Cleary EJ, Brummett RE.

J Acoust Soc Am. 1979 Dec;66(6):1713-8.

PMID:
521555
14.

2AFC versus standard clinical measurement of high frequency auditory sensitivity (8--20 KC/S).

Fausti SA, Frey RH, Erickson DA, Rappaport BZ.

J Aud Res. 1979 Apr;19(2):151-7.

PMID:
549909
15.

An investigation of the effect of bumetanide on high frequency (8 - 20 kHz) hearing in humans.

Fausti SA, Frey RH, Rappaport BZ, Erickson DA.

J Aud Res. 1978 Oct;18(4):243-50. No abstract available.

PMID:
756865

Supplemental Content

Loading ...
Support Center